FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced a 1-for-20 reverse stock split expected to take effect at 12:01 a.m. ET on March 30, 2026, to regain compliance with Nasdaq's minimum bid price requirement.

Post-split outstanding shares will decrease from 70,256,883 to approximately 3,512,845, fractional shares rounded up, and trading will continue under the ticker FBLG.

Positive

• Expected to regain Nasdaq minimum bid price compliance
• Reduces outstanding shares from 70,256,883 to ~3,512,845
• May broaden potential investor interest post-split

Negative

• Reverse split does not change authorized share counts
• Proportionate adjustment to equity awards may affect option liquidity

News Market Reaction – FBLG

-16.51%

10 alerts

-16.51% News Effect

-22.9% Trough in 19 hr 2 min

-$4M Valuation Impact

$17.96M Market Cap

0.5x Rel. Volume

On the day this news was published, FBLG declined 16.51%, reflecting a significant negative market reaction. Argus tracked a trough of -22.9% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $17.96M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Reverse split ratio: 1-for-20 Pre-split shares: 70,256,883 shares Post-split shares: 3,512,845 shares +5 more

8 metrics

Reverse split ratio 1-for-20 Board-approved reverse stock split of common stock

Pre-split shares 70,256,883 shares Issued and outstanding common stock before reverse split

Post-split shares 3,512,845 shares Outstanding common stock after reverse split (subject to fractional adjustment)

Effective date March 30, 2026 Reverse split effective at 12:01 a.m. Eastern Time

Patent portfolio 270+ patents Patents issued and pending cited in company description

Current price $0.2635 Pre-split trading price before reverse split announcement context

52-week high $1.53 52-week high price prior to reverse split news

52-week low $0.2201 52-week low price prior to reverse split news

Market Reality Check

Price: $0.2200 Vol: Volume 623,955 is 0.51x t...

low vol

$0.2200 Last Close

Volume Volume 623,955 is 0.51x the 20-day average of 1,233,506, indicating subdued trading ahead of the reverse split. low

Technical Shares at $0.2635 are trading below the $0.45 200-day moving average, reflecting a sustained downtrend into the split.

Peers on Argus

Momentum data flags a mixed picture: ICU up 2.630000002682209% and XCUR down 2.3...

1 Up 1 Down

Momentum data flags a mixed picture: ICU up 2.630000002682209% and XCUR down 2.380000054836273%. With only one peer moving each way and the scanner marking false for a sector move, the setup around FBLG appears stock-specific.

Common Catalyst Only one tracked peer, ICU, reported earnings today, suggesting no broad biotech-wide catalyst tied to this reverse split announcement.

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Burn therapy update	Positive	-0.0%	Announced CYWC628 expansion into acute and chronic burn treatment models.
Mar 05	Clinical trial progress	Positive	+11.6%	Completed site onboarding for Phase 1/2 CYWC628 diabetic foot ulcer trial.
Mar 02	Patent issuance	Positive	+27.7%	Issued U.S. patent covering fibroblast cell therapy for osteoporosis treatment.
Feb 26	Conference appearance	Positive	+7.4%	Announced CEO presentation and meetings at BIO Investment & Growth Summit.
Feb 24	Earnings and update	Positive	-1.6%	Reported 2025 results, capital raised, debt repaid, and upcoming clinical milestones.

Pattern Detected

Recent FBLG news has generally been positive, with most updates (clinical, IP, conferences) followed by upward price moves, though a few constructive announcements have seen flat or slightly negative reactions.

Recent Company History

Over the past month, FibroBiologics has reported several milestones, including a full-year 2025 update on Feb 24, conference participation on Feb 26, a new osteoporosis patent on Mar 2, clinical site onboarding for CYWC628 on Mar 5, and burn-treatment advances on Mar 12. Most of these events carried constructive clinical or strategic implications and often coincided with positive single-day price reactions, framing today’s reverse split as a capital-markets step alongside ongoing pipeline and IP development.

Market Pulse Summary

The stock dropped -16.5% in the session following this news. A negative reaction despite the complia...

Analysis

The stock dropped -16.5% in the session following this news. A negative reaction despite the compliance-driven rationale would fit a common pattern where reverse splits raise concerns about underlying weakness. FBLG sat far below its $1.53 52-week high at $0.2635 before the 1-for-20 split was announced, and outstanding shares are being consolidated from 70,256,883 to about 3,512,845. Such structural changes can heighten uncertainty around future capital needs and trading dynamics.

Key Terms

reverse stock split, nasdaq capital market, equity incentive plans, warrants, +1 more

5 terms

reverse stock split financial

"announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s issued"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

nasdaq capital market regulatory

"trading on a split-adjusted basis beginning on The Nasdaq Capital Market upon the commencement of trading"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

equity incentive plans financial

"The reverse split will also proportionately adjust the number of shares available under the Company’s equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

warrants financial

"and the exercise price and number of shares underlying outstanding stock options, warrants, and other equity awards"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

cusip number technical

"The new CUSIP number for the Company’s common stock following the reverse stock split will be 31573L204."

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

AI-generated analysis. Not financial advice.

Reverse Split Expected to Take Effect March 30, 2026

HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock. The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on March 30, 2026, with trading on a split-adjusted basis beginning on The Nasdaq Capital Market upon the commencement of trading on Monday, March 30, 2026 under the Company’s existing ticker symbol, “FBLG.”

At the effective time, every 20 shares of FibroBiologics’ issued and outstanding common stock will automatically be combined into one share of common stock. The reverse stock split will reduce the number of shares of the Company’s outstanding common stock from 70,256,883 shares to approximately 3,512,845 shares, subject to adjustment for fractional shares. The number of authorized shares of common stock and preferred stock under the Company’s amended and restated certificate of incorporation, as amended, will not be reduced in connection with the reverse stock split.

The reverse stock split was previously approved by the Company’s stockholders at the special meeting of stockholders held on February 20, 2026, which authorized the Board of Directors to implement a reverse split. The Board determined that implementing the reverse split at this time is appropriate to regain compliance with the minimum bid price requirement for maintaining the listing of the Company’s common stock on The Nasdaq Capital Market and to broaden potential investor interest.

No fractional shares will be issued in connection with the reverse stock split. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole share. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company, except for adjustments related to fractional shares. The reverse split will also proportionately adjust the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding stock options, warrants, and other equity awards, in each case in accordance with their terms.

VStock Transfer, LLC, is acting as the exchange agent for the reverse stock split. Stockholders holding shares in book-entry form or through a brokerage account will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take any action. The new CUSIP number for the Company’s common stock following the reverse stock split will be 31573L204.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

What is the reverse stock split for FibroBiologics (FBLG) and when does it take effect?

The company is implementing a 1-for-20 reverse split effective March 30, 2026 at 12:01 a.m. ET. According to the company, trading on a split-adjusted basis will begin on Nasdaq at the open on Monday, March 30, 2026 under ticker FBLG.

How many FibroBiologics (FBLG) shares will be outstanding after the reverse split?

Outstanding shares will drop to approximately 3,512,845 following the 1-for-20 split. According to the company, the current 70,256,883 issued and outstanding shares will be combined into roughly 3,512,845 shares, subject to adjustment for fractional shares.

Will FibroBiologics (FBLG) shareholders need to take action for the March 30, 2026 reverse split?

No action is required by shareholders; positions will be automatically adjusted. According to the company, book-entry and brokerage account holdings will reflect the split automatically and VStock Transfer will act as the exchange agent.

How will the FibroBiologics (FBLG) reverse split affect stock options, warrants, and equity plans?

Equity awards will be proportionately adjusted in accordance with their terms to reflect the 1-for-20 split. According to the company, the number of shares and exercise prices for options, warrants, and equity awards will be changed proportionally.

What happens to fractional shares from the FibroBiologics (FBLG) reverse stock split?

Fractional shares will not be issued; they will be rounded up to the nearest whole share. According to the company, any fractional share resulting from the reverse split will be rounded up rather than paid out in cash.